Claims
- 1. A pharmaceutical composition comprising:
a molecule selected from the group consisting of a GLP1 molecule, and GRF molecule and a PTH molecule; an acid having a dissociation constant value of greater than 1×10−5; and an excipient; wherein the pH of said composition is between about 3.0 and 5.0.
- 2. The composition according to claim 1, wherein said acid comprises acetic acid.
- 3. The composition according to claim 1, wherein said excipient is D-mannitol.
- 4. The composition according to claim 1 wherein said acid is acetic acid and said excipient is D-mannitol.
- 5. A composition according to claim 1, wherein said composition comprises GLP-1(7-36)amide.
- 6. The composition according to claim 1, wherein said composition comprises GRF(1-44)amide.
- 7. The composition according to claim 1, wherein said composition comprises PTH(1-34)OH.
- 8. The composition of claim 1, wherein said composition is in unit dosage form.
- 9. The composition of claim 1, wherein said composition is sterile.
- 10. A system for administering a pharmaceutical composition comprising:
an infusion pump for administering a unit dose of the composition according to claim 1.
- 11. A system of claim 10, wherein said composition is diluted up to about 40-fold with isotonic saline prior to administration.
- 12. A method for the treatment of a disease or condition in a mammal comprising administering to the mammal a pharmaceutically effective amount of a composition according to claim 1.
- 13. The method of claim 12, wherein the disease or condition is selected from the group consisting of diabetes, excess appetite, obesity, stroke, ischemia, reperfusion injury, disturbed glucose metabolism, surgery, coma, shock, gastrointestinal disease, digestive hormone disease, atherosclerosis, vascular disease, gestational diabetes, liver disease, liver cirrhosis, glucorticoid excess, Cushings disease, the presence of activated counterregulatory hormones that occur after trauma or a disease, hypertriglyceridemia, chronic pancreatitis, the need for parenteral feeding, osteoporosis, and a catabolic state following surgery or injury.
- 14. The method of claim 12, wherein said composition is administered to said mammal by a method selected from the group consisting of intravenous, subcutaneous, continuous, intermittent, parenteral, and combinations thereof.
Parent Case Info
[0001] This application claims priority to U.S. Ser. No. 60/205,377, filed May 17, 2000 and U.S. Ser. No. 60/205,262, filed May 19, 2000, both of which are incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60205377 |
May 2000 |
US |
|
60205262 |
May 2000 |
US |